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Abstract: KRAS and BRAF mutations lead to the constitutive activation of EGFR signaling through the oncogenic Ras/Raf/Mek/Erk 
pathway. Currently, KRAS is the only potential biomarker for predicting the efficacy of anti-EGFR monoclonal antibodies (mAb) in  
colorectal cancer (CRC). However, a recent report suggested that the use of cetuximab was associated with survival benefit among  
patients with p.G13D-mutated tumors. Furthermore, although the presence of mutated BRAF is one of the most powerful prognostic  
factors for advanced and recurrent CRC, it remains unknown whether patients with BRAF-mutated tumors experience a survival   
benefit from treatment with anti-EGFR mAb. Thus, the prognostic or predictive relevance of the KRAS and BRAF genotype in CRC  
remains controversial despite several investigations. Routine KRAS/BRAF screening of pathological specimens is required to promote the 
appropriate clinical use of anti-EGFR mAb and to determine malignant phenotypes in CRC. The significance of KRAS/BRAF  
mutations as predictive or prognostic biomarkers should be taken into consideration when selecting a KRAS/BRAF screening assay.  
This article will review the spectrum of KRAS/BRAF genotype and the impact of KRAS/BRAF mutations on the clinicopathological  
features and prognosis of patients with CRC, particularly when differentiating between the mutations at KRAS codons 12 and 13.   
Furthermore, the predictive role of KRAS/BRAF mutations in treatments with anti-EGFR mAb will be verified, focusing on KRAS 
p.G13D and BRAF mutations. 
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INTRODUCTION 
  The development of colorectal cancer (CRC) is a multistep 
process that occurs because of the accumulation of several genetic 
alterations, including chromosomal abnormalities, gene mutations, 
and epigenetic modifications involving several genes that regulate 
proliferation, differentiation, apoptosis, and angiogenesis [1, 2]. 
  Of the various genetic alterations, an important molecular target 
for metastatic CRC treatment is the epidermal growth factor recep-
tor (EGFR). EGFR, also known as HER1 or ErbB, is a 170-kD 
receptor tyrosine kinase and belongs to the ErbB receptor family. 
There are four members in the ErbB receptor family: ErbB1 
(EGFR, HER1), ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 
(HER4). The binding of several specific ligands, such as EGF, 
TGF-, or amphiregulin, results in the dimerization of EGFR and 
subsequent phosphorylation of several tyrosine residues [3, 4]. 
These phosphorylated tyrosines serve as binding sites for several 
signal transducers that initiate multiple signaling pathways, includ-
ing the Ras/Raf/MAP/MEK/ERK and/or PTEN/PI3K/Akt path-
ways. Although EGFR plays important roles in cell differentiation 
and proliferation in normal cells, the activation of EGFR signaling 
is frequently observed in CRC cells, where it results in cell prolif-
eration, migration and metastasis, evasion of apoptosis, or angio-
genesis [5]. Approximately 35% CRC tissues carry a mutation at 
codon 12 or 13 of KRAS that leads to the constitutive activation of 
EGFR downstream pathways [6-10]. 
  Information on the KRAS/BRAF genotype is also extremely 
useful when selecting systemic chemotherapy for advanced and 
recurrent patients with CRC, where it can help identify patients 
with poor prognoses. KRAS and BRAF are currently under focus as 
potential prognostic and predictive biomarkers in patients with 
metastatic diseases treated with anti-EGFR monoclonal antibodies 
(mAb), such as cetuximab and panitumumab [11-14]. Several retro-
spective analyses revealed that cetuximab treatment is ineffective in 
patients with KRAS mutations, thereby suggesting that the KRAS 
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genotype is a useful predictive biomarker for cetuximab or panitu-
mumab therapy in CRC [11-13, 15]. It has also been suggested that 
wild-type BRAF is required for a successful response to panitumu-
mab or cetuximab therapies in patients with metastatic CRC [9, 10, 
16, 17]. However, the prognostic relevance of the KRAS genotype 
in CRC remains controversial despite several multi-institutional 
investigations since the 1990s [18-22]. 
  In this article, I will review the spectrum of the KRAS/BRAF 
genotype and the clinical outcomes of KRAS/BRAF mutations in 
patients with CRC. The prognostic and/or predictive impact of 
KRAS/BRAF mutations will then be discussed, focusing on the dif-
ference between mutations at KRAS codons 12 and 13. 
POTENTIAL PREDICTIVE BIOMARKERS FOR ANTI-
EGFR THERAPY 
  The molecular mechanisms underlying response or resistance to 
anti-EGFR mAb still remain largely unknown. However, the clini-
cal predictive factors that indicate the response or resistance to anti-
EGFR therapy should be identified before beginning such a treat-
ment in patients with CRC to prevent drug-induced toxicity and 
avoid unnecessary expenses. The main research areas in this setting 
have been focusing on the role of (i) EGFR protein expression, (ii) 
EGFR gene copy number, (iii) EGFR gene mutations, (iv) overex-
pression of EGFR ligands (such as epiregulin and amphiregulin), 
(v) methylation of the EGFR promoter, and (vi) markers of EGFR 
downstream signaling [8, 9, 23-28].  
  For initial clinical trials, patients with metastatic CRC were 
selected if they had tumors positive for the expression of EGFR as 
detected by immunohistochemistry (IHC). However, cetuximab is 
also effective in patients with CRC having tumors that do not ex-
press EGFR when examined by IHC [29]. Indeed, EGFR is overex-
pressed in 30%–85% patients with CRC. Therefore, the level of 
EGFR protein expression has proved to be poorly associated with 
sensitivity to anti-EGFR mAb. Inconsistent methodology and inter-
pretation of EGFR IHC expression in tumor samples may be an 
explanation for this. Inter-observer variability in the definitions of 
the expression EGFR may depend on the tissue fixation technique 
used, possibly leading to false negative samples by IHC using par-
affin-embedded tumor tissues. Significant differences in EGFR IHC 
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expression between a patient’s primary tumor and their metastatic 
tissue specimen may be another explanation. The primary tumor is 
frequently used to establish the patient’s EGFR status, but metasta-
ses are treated with cetuximab. A third explanation is that high-
affinity EGFRs are the predominant biologically active receptors 
that lead to the activation of protein tyrosine kinase, thereby con-
tributing significantly to signal transduction [30]. However, the 
anti-EGFR antibodies that are most commonly used do not distin-
guish between high-affinity and low-affinity EGFRs [31]. Another 
potential explanation may be the potential of cetuximab to induce 
antibody-dependent cell-mediated cytotoxicity (ADCC) despite an 
equivalent pharmacological EGFR blockade. 
  In a small fraction of CRCs, the overexpression of EGFR is 
frequently associated with amplification of the gene. The EGFR 
gene copy number evaluated by quantitative PCR does not appear 
to correlate with the clinical outcome of patients, whereas the result 
of the analysis by fluorescence in situ hybridization (FISH) appears 
to be associated with an increase in treatment response [32]. How-
ever, the predictive value is uncertain, and further studies are re-
quired to assess the increase of EGFR gene copy number as a pre-
dictive biomarker of response to anti-EGFR therapy. Activating 
mutations in the EGFR catalytic domain plays an important role  
in determining the responsiveness to anti-EGFR therapy in lung 
cancer. However, mutations in the EGFR tyrosine kinase domain 
are considered to be extremely rare in patients with CRC [33] and 
they are not significantly associated with the clinical response of 
metastatic CRC to anti-EGFR mAb [24]. 
  The overexpression of alternative EGFR ligands, such 
epiregulin and amphireguline, may promote tumor growth and sur-
vival by an autocrine loop [34]. Several studies have correlated the 
expression of these ligands with sensitivity to cetuximab mono- 
therapy. The results showed a statistically longer progression-free 
survival (PFS) period among patients with high expression of 
epiregulin. The exclusive use of an amphiregulin or epiregulin   
gene expression profile does not, however, result in the selection of 
patient populations benefiting from cetuximab treatment [35]. 
 Scartozzi  et al., investigated the correlation between the   
efficacy of irinotecan plus cetuximab therapy and methylation 
status in the EGFR promoter [36]. Patients with tumors harboring 
the hypermethylating EGFR promoter experienced a worse clinical 
outcome in terms of progression-free survival (PFS) and overall 
survival (OS), suggesting that the methylation of EGFR promoter 
plays a role in determining the efficacy of anti-EGFR mAb. Thus, 
the hypermethylation of EGFR promoter may be a valuable and 
important indicator that should be considered in further investiga-
tions of the role of EGFR as a therapeutic target in patients with 
CRC. 
  Collectively, the predictive value of alterations in EGFR   
expression level remains unconvincing in the use of anti-EGFR 
therapy. Therefore, the focus has shifted to alterations of the key 
signaling pathway downstream of EGFR. 
BIOMARKERS DOWNSTREAM OF EGFR 
  The constitutive activation of signaling pathways downstream 
of EGFR drive the growth and progression of CRC and provide  
an escape mechanism that allows tumors to overcome the phar- 
macological blockade induced by anti-EGFR mAb [37]. KRAS, 
BRAF, PTEN, and PI3KCA mutations have been highlighted as the 
mechanisms that activate EGFR signaling pathway. 
  KRAS is a proto-oncogene encoding a small 21-kD guanosine 
triphosphate (GTP)/guanosine diphosphate (GDP) binding protein 
involved in the regulation of the cellular response to many extracel-
lular stimuli [38]. After binding and activation by GTP, KRAS  
recruits the oncogene BRAF, which phosphorylates MAP2K   
(mitogen-activated protein kinase kinase), thereby initiating MAPK 
signaling leading to the expression of the protein involved in cell 
proliferation, differentiation, and survival [39]. KRAS is the mostly 
commonly mutated gene in this pathway, and 35%–45% patients 
with CRCs carry this mutation, which is an early event in colon 
tumorigenesis [40]. KRAS mutations frequently induce glycine-to-
valine substitutions at the catalytic sites of amino acids, which leads 
to the loss of GTPase activity and subsequent continuous binding  
of GTP to RAS. This constitutive activation of RAS results in the 
dysregulation of the downstream RAS-ERK signaling pathway 
independently of EGFR. Similarly, the kinase activity of the BRAF 
mutant protein is greatly elevated, which also constitutively   
stimulates downstream ERK activity independently of RAS   
and EGFR. Thus, the constitutive activation of KRAS or BRAF 
mutation leads to EGFR-independent tumorigenicity in patients 
with CRC. Therefore, the oncogenic activation of the RAS signaling 
pathway impairs the response of colorectal cancer cells to cetuximab 
[6-10, 41]. 
  The PTEN/PI3K/Akt pathway also affects several cellular proc-
esses such as cell proliferation, apoptosis, and invasion [42]. Signal 
transduction through this pathway is mediated by conversion of 
phosphatidylinositol bisphosphate (PIP2) to phosphatidylinositol 
triphosphate (PIP3) by phosphatidylinositol 3 kinases (PI3K)   
following their activation, and this reaction is antagonized by phos-
phatase and a tensin homolog deleted on chromosome ten (PTEN). 
The  PTEN mutation is known to correlate with microsatellite   
instability (MSI-H) in patients with CRC [43, 44]. Of the genes that 
encode the enzymatic subunit of PI3K heterodimers, the PIK3CA 
gene that encodes the p110 subunit of PI3K has been found to be 
most frequently activated by its mutations in some human cancers 
[42]; this promotes AKT1 phosphorylation to activate a parallel 
intracellular axis [45].  
  Several reports have suggested that there is cross-talk between 
Ras/Raf/MAP/MEK/ERK and/or PTEN/PI3K/Akt pathways.   
Specifically, PIK3CA can be activated via interaction with the RAS 
protein [46]. 
SPECTRUM OF THE KRAS AND BRAF GENOTYPES IN 
PATIENTS WITH CRC  
  Estimates of the KRAS mutation frequency in metastatic CRCs 
are based on selective clinical studies or drug admission trials with 
variable inclusion criteria. According to previous investigations on 
the spectrum of the KRAS genotype in our database of CRC cases, 
the most frequent mutations at the KRAS codon 12 were G12D, 
G12V, G12R, G12C, G12S, and G12A, which accounted for more 
than 95% of the codon 12 mutations. The G13D and G13C muta-
tions at codon 13 and the G61H, G61L, G61E, and G61K mutations 
at codon 61 were the most common mutations that occurred at these 
codons [47]. All these KRAS mutations have been previously de-
scribed as oncogenically active and they are present in the COS-
MIC (catalog of somatic mutations in cancer) database [48]. Data 
from a large Japanese population of patients with advanced and 
recurrent CRC revealed that KRAS mutations were present in   
approximately 35% patients with CRC of which 25% patients   
had mutations at codon 12 and 10% patients had mutations at codon 
13. This observation was consistent with that of previous studies on 
selected cohorts that reported frequencies in the range of 30%–42% 
[47]. 
  Although more than 40 somatic mutations have been described 
in the BRAF kinase domain, the most common mutation across 
various cancers is the classic GTGGAG substitution at position 
1799 of exon 15, which results in the V600E amino acid change 
and subsequent constitutive activation of the EGFR signaling path-
way. Functionally, this is the most important mutation involved in 
the receptor-independent aberrant activation of the EGFR signaling 
pathway and CRC carcinogenesis. Recent studies in western coun-
tries suggested that BRAF mutations occur in 10%–20% of patients 
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the Japanese population was observed in 4.7% patients with CRC; 
this appeared to be lower than that found in western populations. 
None of the patients with CRC carried both KRAS and BRAF muta-
tions, supporting the hypothesis that KRAS and BRAF mutations   
are mutually exclusive [51-53]. One possible explanation for   
the comparatively low frequency of BRAF mutations might be the 
difference in ethnicities. Indeed, several studies reported that the 
mutation rates of DNA mismatch repair (MMR) genes, such as 
hMSH2 and hMLH1, in hereditary non-polyposis colorectal cancer 
(HNPCC) varies across countries. Therefore, geographical variation 
may account for the differences in the mutation spectrum of BRAF, 
as observed for MMR genes [54-56]. 
KRAS TESTING IS A SCREEN FOR DRIVER MUTATION, 
BUT NOT FOR SUPER-RESPONDER  
 Routine  KRAS/BRAF screening should be performed before 
initiating anti-EGFR therapy in patients with CRC to predict non-
responsiveness to anti-EGFR therapy and to prevent drug-induced 
toxicity. In addition, limiting the use of anti-EGFR mAb to patients 
with wild-type, i.e., non-mutated, KRAS testing may result in avoid-
ing heavy expenses [57]. Therefore, optimal KRAS/BRAF geno- 
typing procedures with pathological specimens are necessary. The 
significance of KRAS/BRAF mutations as predictive markers in 
patients with CRC should be considered while selecting a method 
for  KRAS testing. Patients with non-small cell lung cancer 
(NSCLC) show 30% EGFR mutations and 5% ALK translocations, 
which are driver mutation targeted by molecular target agents such 
as Gefitinib or ALK inhibitors. Because the populations with these 
gene alterations are super responders to specific molecular target 
therapies, screening for driver mutations is essential and requires a 
technique with high sensitivity. In patients with CRC, KRAS testing 
is also a screen for a driver mutation. However, unlike NSCLC, the 
main purpose of KRAS genotyping in patients with CRC is screen-
ing for absolute non-responders to anti-EGFR mAb (Fig. 1). 
  Allele-specific PCR methods such as TaqMan MGB Probes or 
ScorpionsARMS are available as commercial test kits, and some 
clinical trials have applied this method for KRAS genotyping. Scor-
pionsARMS is believed to be more sensitive than both direct se-
quencing and cycleave PCR and can detect mutations in samples 
containing 1% mutant allele sequences. However, optimal KRAS 
genotyping methods may not necessarily be highly sensitive. The 
most critical mistake that should be avoided is an overestimation of 
the population with KRAS mutations that would lead to depriving 
true responders of the benefits of anti-EGFR mAb. Furthermore, 
allele-specific PCR methods such as TaqMan MGB Probes or 
ScorpionsARMS are too expensive to be used as routine diagnostic 
methods for KRAS genotyping [47]. 
  Taken together, appropriate methods should be selected for 
KRAS genotyping, taking into consideration KRAS mutations as 
negative predictive biomarkers. 
ASSOCIATION OF BRAF/KRAS MUTATIONS WITH 
CLINICOPATHOLOGICAL FEATURES 
  Several reports suggested that tumors harboring BRAF muta-
tions have different clinical and histopathological features com-
pared with tumors harboring KRAS mutations. BRAF mutations 
occur more frequently in right-sided tumors [58-61]. A study evalu-
ating the correlation between KRAS/BRAF mutational status and 
clinicopathological features in advanced and recurrent CRC also 
found that in 60% patients with CRCs having BRAF mutations, the 
tumor metastasized to the peritoneum compared with approximately 
15% patients with CRCs with other subtypes. Furthermore, 60% 
BRAF mutation-positive specimens belonged to poorly differenti-
ated adenocarcinoma or mucinous carcinoma subtypes [61]. It was 
recently reported that mucinous histology indicates a poor response 
to oxaliplatin- and/or irinotecan-based chemotherapies and is corre-
lated with poor OS [62]. Because BRAF mutations are more fre-
quent in mucinous carcinomas than in non-mucinous carcinomas as 
demonstrated by the present study and a previous study [63], the 
poor prognosis associated with mucinous histology may be at least 
partially explained by the poor prognosis of patients with CRC 
having BRAF mutations. These specific clinicopathological features 
support the hypothesis that BRAF mutation-mediated carcinogene-
sis in patients with CRC is initiated by altered BRAF function as an 
early step in the serrated pathway [64] that leads to the activation of 
EGFR signaling. In contrast to BRAF mutations, no significant 
differences have been observed in clinicopathological parameters 
based on the KRAS genotype in many studies, probably due to the 
lack of differentiation between KRAS12 mutations and KRAS13 
mutations. However, an analysis in which a population of patients 
with CRC was categorized into four subtypes—KRAS and BRAF 
(wild/wild),  KRAS12 mutations, KRAS13 mutations, and BRAF 
mutations (V600E), suggested that KRAS13 mutations were also 
associated with right-sided tumors [61]. This suggests the possibil-
ity that KRAS13 may have a phenotype distinct from that of other 
KRAS genotypes. 
PROGNOSTIC ROLE OF KRAS MUTATIONS 
  The prognostic value of KRAS mutations in patients with CRC 
remains controversial. Although the prognostic role of KRAS muta-
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tions has been previously investigated, no definitive conclusions 
have been drawn [65]. This may be because of differences in terms 
of study size, patient selection, tumor sampling, use of archival 
versus fresh/frozen material, laboratory methods, and data analyses. 
Furthermore, such prognostic analyses are performed mostly in 
homogeneous groups of metastatic patients with CRC treated with a 
specific chemotherapy regimen with or without cetuximab [14, 66] 
(Table 1). 
  A recent translational study by Roth et al., suggested that the 
prognostic value for KRAS mutation status for PFS and OS was 
lacking in PETACC-3, EORTC 40993, and SAKK 60-00 trials of 
patients with stage II and III resected colon cancer [22]. However, it 
has been reported that stage III patients having KRAS mutations 
displayed significantly worse disease-free survival compared with 
those having wild-type KRAS [50]. Furthermore, an N0147 trial 
assessing the potential benefit from cetuximab treatment combined 
with FOLFOX in patients with resected stage III CRC showed that 
the three-year disease-free survival in patients with wild-type KRAS 
was significantly better than that in patients with KRAS mutants 
(72.3% versus 64.2%, HR = 0.7, p = 0.004) (Table 1). These analy-
ses suggest that KRAS mutations are independent prognostic factors 
[67]. A Medical Research Council (MRC) COIN trial assessed the 
effects of cetuximab combined with oxaliplatin and fluoro-
pyrimidine chemotherapy as a first-line treatment of patients with 
advanced CRC. This trial found that the median OS was signifi-
cantly shorter in patients with KRAS, NRAS, or BRAF mutations  
(n = 706, 13.6 months) compared with those with wild types for 
KRAS, NRAS, and BRAF (n = 581, 20.1 months), irrespective of the 
treatment [68]. 
  More importantly, few studies have differentiated KRAS muta-
tions at codon 12 from those at codon 13 with respect to clinicopa-
thological features and survival. Recent findings have suggested 
that CRC with a KRAS mutation is not clinically homogeneous but 
heterogeneous population [69]. This hypothesis may be supported 
by the fact that NSCLCs harboring alterations in the EGFR gene are 
biologically and pharmacologically heterogeneous. Indeed, there 
are differences in the transforming potential and EGFR tyrosine 
kinase inhibitor (TKI) sensitivity associated with EGFR somatic 
mutations L858R and the deletion mutant Del (746–750) in 
NSCLCs [70]. 
  Collaborative RASCAL II studies were conducted to investi-
gate the prognostic role of KRAS mutations in CRC progression. To 
explore the effect of KRAS mutations at different stages of CRC, 
3493 patients were recruited in this multivariate analysis. RASCAL 
studies showed that tumors carrying a substitution of glycine to 
valine at codon 12, which was found in 8.6% patients, had a statis-
tically significant impact on worse PFS (p = 0.0004, HR = 1.3) and 
OS (p = 0.008, HR = 1.29) [40]. This clinical data was supported by 
the finding that KRAS12 mutations confer a more aggressive trans-
forming phenotype than KRAS13 mutations through a significant 
increase in the activation of AKT and expression of bcl-2, and a 
significant decrease in the expression of RhoA [71]. However, mul-
tivariate analysis by Bazan et al., revealed that KRAS13 mutations, 
but not other mutations, were independently related to the risk of 
relapse or death in a consecutive series of 160 untreated patients 
(median of follow up period = 71 months) who underwent resective 
surgery for primary CRC [72]. Consistent with this study, Yokota  
et al., examined 229 patients with advanced and recurrent CRC 
who were treated with systemic chemotherapy, and demonstrated 
that the OS for patients with KRAS13 mutations was significantly 
worse than for those who had wild-type KRAS and wild-type BRAF, 
whereas KRAS12 mutation did not affect patient OS [61]. Further-
more, KRAS/BRAF genotype was analyzed in a large subgroup of 
845 patients with metastatic CRCs who received FOLFIRI and 
FOLFOX chemotherapy with or without cetuximab as the first-line 
treatment in the CRYSTAL and OPUS studies, respectively [66]. 
The results revealed that KRAS13D mutations are associated with 
poor prognosis. Therefore, the finding that stage III patients with 
KRAS mutations displayed significantly worse disease-free survival 
than those with wild-type KRAS [50, 64, 67], might be partially   
explained by the impact of either KRAS12 or KRAS13 mutations on 
prognosis. 
  Taken together, differences in KRAS mutations at codons 12 
and 13 may result in different biological, biochemical, and func-
tional consequences that could influence the prognosis of CRC 
[72]. Larger studies are required to confirm whether a specific 
KRAS mutation might lead to a clinically relevant prognostic effect 
in patients with CRC. 
ARE  KRAS MUTATIONS NEGATIVE PREDICTIVE   
BIOMARKERS FOR ANTI-EGFR mAB? 
  Several retrospective analyses have revealed that patients with 
KRAS mutations receiving first and subsequent lines of treatment do 
not respond to cetuximab or panitumumab, and that they show no 
survival benefit from such treatments [11-13, 15, 73]. KRAS muta-
tions have emerged as a major predictor of resistance to anti-EGFR 
Table 1.  KRAS Mutation and Prognosis 
Overall Survival (month) 
Trial Population  Therapy 
KRAS wt  KRAS mut 
HR P-value  Prognostic  ? 
CO.17 3rd  line  BSC  4.8  4.6  1.01  0.97  No 
CAIRO-2  1st  line  CapeOX+BV 22.4  24.9   0.82 No 
N0147  Stage III  FOLFOX+Cmab  *72.3 %  *64.2 %  0.7  0.004  Yes 
COIN 1st  line  FU+OX+/-Cmab  17.5  14.4    <0.0001  Yes 
Fariña-Sarasqueta, A. et al. Stage  III  -  ?  ?    0.03  Yes 
PETACC-3  Stage  II/III  FU/LV+/-CPT-11    1.09  0.48 No 
FOCUS  1st line sequential  FU+/-CPT-11/OX  ?  ?  1.24  0.008  Yes 
Van Cutsem, E.   et al. 3rd  line  BSC  7.6 4.4    **N.S.  No 
EPIC 2nd  line  CPT-11  11.56  10.68    **N.S.  No 
*; 3 year Disease free survival, **; statistically not significant  
Abbreviations: BSC, best supportive care; Cape, capecitabine; OX, oxaliplatin; Cmab, cetuximab; mut, mutated. KRAS and BRAF as Prognostic and Predictive Markers in CRC  Anti-Cancer Agents in Medicinal Chemistry, 2012, Vol. 12, No. 2    167 
mAb in the clinical setting. Therefore, patients with metastatic CRC 
with KRAS codon 12- or KRAS codon 13-mutated tumors are pres-
ently excluded from treatment with anti-EGFR mAb. 
  However, one patient with a mutated KRAS tumor (1.2%) had a 
response in the CO.17 trial comparing cetuximab monotherapy with 
best supportive care (BSC) in patients with chemotherapy-
refractory metastatic CRC [11]. Furthermore, a recent retrospective 
analysis by De Roock et al., examined 579 patients with chemo-
therapy-refractory CRC who received cetuximab treatment, and 
revealed that patients with p.G13D-mutated tumors showed a trend 
toward a higher response rate than other KRAS-mutated tumors 
(6.3% versus 1.6%, p = 0.15). Strikingly, patients with KRAS codon 
p.G13D mutations who received cetuximab experienced longer 
progression-free and overall survival compared with BSC alone. In 
contrast, patients with other KRAS mutations did not appear to 
benefit from cetuximab. The authors suggested that p.G13D-
mutated tumors may have a worse prognosis, based on the finding 
that patients with KRAS p.G13D mutations who received BSC 
alone showed significantly shorter survival compared with those 
with other KRAS mutations in the CO.17 study [74].  
  Furthermore, the association of KRAS  p.G13D mutation 
with clinical outcome was investigated in a pooled analysis of pa-
tients from the CRYSTAL and OPUS studies. The population con-
sisted of 689 patients in each treatment arm, including 447 versus 
398 with wild-type KRAS, 41 versus 42 with KRAS p.G13D, and 
201 versus 249 with other KRAS mutations, for chemotherapy alone 
and cetuximab plus chemotherapy arms, respectively. A heteroge-
neous treatment effect was observed with significant treatment 
interaction with the KRAS mutation status for response (p < 0.0001), 
PFS (p < 0.0001), and OS (p = 0.0219). In particular, the response 
rate in patients with KRAS p.G13D treated with cetuximab plus 
chemotherapy was better than that in those treated with chemother-
apy alone (40.5% versus 22.0%; 95% CI, 0.90 to 6.45, p = 0.0748). 
The hazard ratio for PFS among patients with KRAS p.G13D was 
0.60 (95% CI, 0.32 to 1.12, p = 0.1037), while that for OS among 
patients with KRAS p.G13D was 0.80 (95% CI, 0.49 to 1.30) in 
favor of the cetuximab plus chemotherapy arm. Although treatment 
effects were not statistically significant, patients with KRAS 
p.G13D had a similar relative treatment effect compared with   
patients with wild-type KRAS. 
  Taken together, these data may suggest that KRAS p.G13D 
mutations are poor prognostic biomarker, and the use of cetuximab 
may affect prolonged survival in patients receiving first-line   
chemotherapy and those with chemotherapy-refractory metastatic 
colon cancer. The clinical benefit of anti-EGFR therapy in patients 
with KRAS mutations, which are rare, may be partially explained  
by the benefit in p.G13D-mutated group. Further prospectively 
generated clinical investigations are necessary to confirm these 
data, because whether the KRAS p.G13D mutation is an effective 
negative predictive biomarker remains controversial.  
PROGNOSTIC ROLE OF BRAF MUTATIONS 
 A  BRAF mutation (V600E) has been studied in recent years for 
a better understanding of its possible role in prognosis and predict-
ing the response to anti-EGFR mAb. 
  While few studies investigated the impact of KRAS12 and 
KRAS13 mutations on CRC prognosis, a series of recent studies 
confirmed the potential adverse prognostic impact of BRAF muta-
tions (Table 2). Yokota et al., identified BRAF V600E mutation as 
an independent prognostic factor for survival in a representative 
cohort of 229 patients with advanced and recurrent CRC. The pres-
ence of this BRAF mutation was associated with a significantly 
higher risk of dying from cancer-related causes, independently of 
other factors such as age, gender, PS, KRAS status, pathological 
finding, number of metastases, and metastatic sites [61]. This find-
ing is consistent with those of other recent studies using patients 
with both stage II and III disease and patients across all disease 
stages [21, 22, 50]. For example, an analysis of stage II and stage 
III patients with CRC [22, 50] was consistent with the finding that 
44% population had recurrent disease [61]. Furthermore, BRAF 
mutations were correlated with survival in a heterogeneous group of 
patients with CRC that included all disease stages [20] (Table 2). 
Furthermore, BRAF mutations are prognostic biomarkers for OS, 
particularly in patients with microsatellite instability (MSI), both 
low (MSI-L) and stable (MSI-S) tumors. In the high (MSI-H) sub-
population, a prognostic value of KRAS and BRAF mutation status 
was not found for RFS and OS [22] (Table 4). Whereas BRAF  
mutations had no prognostic value in the relapse-free survival of 
stage II-III CRC, BRAF mutation is a strong determinant of OS 
after relapse [22]. 
  Furthermore, the prognostic value of BRAF was analyzed in 
patients with CRC treated with specific chemotherapy regimens in 
clinical trials that evaluated a combination of cetuximab with che-
motherapy (Table 3). The CAIRO-2 study investigated a large se-
ries of metastatic patients with CRC treated with chemotherapy and 
bevacizumab with or without cetuximab in a subgroup of 520 pa-
tients. This study revealed that patients with CRC having BRAF 
mutations show a worse outcome, both in terms of PFS and OS, 
irrespective of the addition of cetuximab to the treatment [14].   
The pooled analysis of the abovementioned CRYSTAL and OPUS 
studies revealed that the outcome of patients with CRC having 
BRAF mutations is worse than that of patients with CRC having 
wild-type BRAF, independently of treatment with cetuximab [66]. 
These findings further support the hypothesis that BRAF mutations 
are negative prognostic biomarkers. The BRAF genotype might   
be an additional stratification factor for future clinical trials of   
advanced and recurrent CRC.  
PREDICTIVE ROLE OF BRAF MUTATIONS 
 Di  Nicolantonio  et al., retrospectively analyzed objective tumor 
responses and survival, and the mutational status of KRAS and 
BRAF in 113 patients with metastatic CRC treated with cetuximab 
or panitumumab [9]. None of the BRAF-mutated patients responded 
to the treatment, while none of the responders carried BRAF muta-
tions. BRAF-mutated patients had significantly shorter progression-
free survival and overall survival than wild-type patients. The effect 
of BRAF V600E mutation on cetuximab or panitumumab response 
was also assessed using cellular models of CRC. The introduction 
of BRAF V600E allele impaired the therapeutic effect of cetuximab 
or panitumumab. Similarly, Souglakos et al., addressed the predic-
tive value of BRAF in 100 patients treated with cetuximab, includ-
Table 2.  BRAF Mutation and Prognosis  
  Population  HR (95% CI)  Reference  Prognostic ? 
Ann Oncol. 2010; 21(12):2396-402  stage II / III   0.45 (0.25–0.8)  Mutant  Yes 
Gut 2009; 58: 90-96  All stage  1.20 (0.79–1.80)  Wild  Yes 
PETACC-3  stage II / III   1.19 (0.84-1.69)  Wild  Yes 
Br J Cancer 2011;104:856-62  Recurrent and advanced  4.25 (2.08–8.67)  Wild  Yes 
Abbreviations: CT, chemotherapy; CB, CapeOX/bevacizumab; CBC, CapeOX/bevacizumab plus cetuximab. 168    Anti-Cancer Agents in Medicinal Chemistry, 2012, Vol. 12, No. 2  Tomoya Yokota 
ing 8 in the first line, 37 in the second, and 55 in the third or higher, 
always in combination with chemotherapy [10]. No patients with a 
BRAF-mutant tumor responded to cetuximab, whereas objective 
responses were observed in 17% patients with wild-type BRAF. 
Patients with BRAF mutation also had a shorter PFS, regardless of 
whether cetuximab was administered in the second or third or 
higher lines. The effects of BRAF status on the efficacy of cetuxi-
mab plus chemotherapy were retrospectively analyzed in patients 
with metastatic CRC having wild-type KRAS [16, 17], indicating 
that the presence of BRAF mutation was significantly correlated 
with lower response rate than wild-type BRAF, with a response rate 
of 8.3% (2/24) in carriers of BRAF mutations versus 38.0% in 
BRAF wild types [17]. These results suggest that wild-type BRAF is 
required for the response to anti-EGFR mAb in metastatic CRC. 
However, these studies lacked data on BRAF-mutated patients 
treated with chemotherapy alone, so they failed to directly compare 
the efficacy of adding cetuximab or panitumumab to chemotherapy 
with that of chemotherapy alone in a cohort of BRAF-mutated  
patients. Therefore, whether BRAF and KRAS mutations are   
negative predictive biomarkers for anti-EGFR mAb cannot be   
ascertained. 
  In the pooled analysis of CRYSTAL and OPUS, patients with 
BRAF mutations seemed to benefit from the addition of cetuximab, 
with an increase of OS and a doubling of PFS rates, although this 
was not statistically significant [66]. The addition of cetuximab to 
FOLFIRI or FOLFOX regimens showed a trend towards better 
survival compared with FOLFIRI or FOLFOX alone. This result 
raises the possibility that the use of cetuximab might be effective 
for disease control at least as the first-line chemotherapy for pa-
tients with wild-type KRAS and mutant BRAF.  
  Taken together, the association of BRAF mutations with the 
efficacy of anti-EGFR therapy remains controversial, but its signifi-
cant negative prognostic value has been established. Such discrep-
ant results among studies might be partially explained by the differ-
ential significance of BRAF mutations as predictive biomarkers for 
anti-EGFR mAb in the first-line and second-line or higher line 
chemotherapy. The relatively low frequency of BRAF mutations in 
patients with CRC makes it relatively difficult to draw absolute 
conclusions, but the present observations should be confirmed by 
examining an increased number of patients with BRAF mutations. 
CONCLUSIONS 
  The activation of EGFR signaling, such as Ras/Raf/MAP/ 
MEK/ERK and/or PTEN/PI3K/Akt pathways, plays an important 
role in tumorigenesis and the tumor progression of CRC. Two pre-
dominant EGFR inhibitors have been developed including mono-
clonal antibodies that target the extracellular domain of EGFR and 
small molecule TKIs that target the receptor catalytic domain of 
EGFR. Although both classes of agents show clear antitumor activ-
ity, only the anti-EGFR mAb has been approved for clinical use in 
the treatment of patients with metastatic CRC. Because the predic-
tive value of alterations in EGFR expression level is unclear in the 
use of anti-EGFR mAb, the focus has shifted to alterations of key 
signaling pathways downstream of EGFR. In particular, KRAS and 
BRAF mutations have been highlighted as the activating mecha-
nisms of the EGFR signaling pathway. Routine screening for 
KRAS/BRAF genotype is extremely important for identifying pa-
tients with shorter survival in response to systemic chemotherapy, 
regardless of the use of anti-EGFR mAb, and for predicting patients 
who would benefit from anti-EGFR mAb treatment, which is costly 
and potentially toxic. However, the significance of KRAS/BRAF 
mutations as prognostic and/or predictive biomarkers in patients 
with CRC should be considered while selecting a method for KRAS 
genotyping. 
  KRAS mutations were observed in approximately 35% patients 
with CRC, of which 25% patients had mutations at codon 12 and 
10% patients had mutations at codon 13. The KRAS genotype is a 
useful predictive biomarker for patients with metastatic CRC that is 
treated with anti-EGFR mAb. Recent reports have raised the possi-
bility that KRAS13 may have a specific phenotype that is different 
from other KRAS genotypes. Therefore, differences in KRAS muta-
tions at codons 12 and 13 may result in different biological, bio-
chemical, and functional consequences and clinical features, which 
may also influence the prognosis of CRC. Indeed, several retrospec-
tive analyses have suggested that KRAS mutations at codon 13, 
particularly KRAS p.G13D, as well as BRAF mutations are prognos-
tic factors. Furthermore, a recent major research finding is that 
patients with KRAS p.G13D, but not other mutations, may experi-
ence a survival benefit from treatment with cetuximab plus chemo-
therapy. These findings also support the hypothesis that patients 
with CRC having KRAS mutations constitute a heterogeneous popu-
lation. Since the prognostic and/or predictive role of KRAS13 muta-
tions continues to remain controversial, further prospective clinical 
investigations are warranted. 
  Several reports have suggested that tumors harboring BRAF 
mutations have distinct clinicopathological features. Importantly, 
BRAF mutations are significant negative prognostic biomarkers in 
patients with recurrent CRC across all disease stages. Moreover, the 
Table 3.  BRAF Mutation and Prognosis in the Clinical Trials Evaluating Combination of Cetuximab with Chemotherapy 
  Population  Therapy  BRAF wt  BRAF mut  P-value  Prognostic ? 
CT 21.1 9.9  -  ASCO2010, Abstract  
No. 3506 
1st line  
CRYSTAL/OPUS  CT+Cmab 24.8  14.1  - 
Yes 
CB 24.6  15.0  0.002  N Engl J Med. 2009;  
361: 98-99 
1st line  
CAIRO-2  CBC 21.5 15.2  0.001 
Yes 
Abbreviations: CT, chemotherapy; CB, CapeOX/bevacizumab; CBC, CapeOX/bevacizumab plus cetuximab.  
 
Table 4.  Are KRAS/BRAF Mutations Predictive and/or Prognostic?  
  KRAS mut  BRAF mut 
  Codon 12 mutant  Codon 13 mutant  Codon 61 mutant  MSI  MSS 
Predictive marker  Negative predictive  Negative predictive?  Negative predictive?  Positive predictive? 
Prognostic marker  No  Yes? ?  No  Yes 
Abbreviations: MSI, microsatellite unstable; MSS, microsatellite stable. KRAS and BRAF as Prognostic and Predictive Markers in CRC  Anti-Cancer Agents in Medicinal Chemistry, 2012, Vol. 12, No. 2    169 
prognostic value of BRAF mutations has been confirmed in patients 
with CRC treated with specific chemotherapy regimens in clinical 
trials evaluating a combination of cetuximab with chemotherapy. 
However, whether BRAF mutations are negative predictive bio-
markers for anti-EGFR mAb has not been ascertained, because the 
controlled study, which directly compared the efficacy of adding 
anti-EGFR mAb to chemotherapy with that of chemotherapy alone, 
is lacking in a small population with BRAF mutations. The applica-
tion of novel strategies targeting BRAF kinase is warranted for the 
treatment of patients with CRC with BRAF mutations to improve 
their poor survival. 
  The mechanism of how anti-EGFR mAb functions is now being 
revealed. However, clinical data suggest that the Ras/Raf/ERK 
pathway is insufficient for completely predicting the response to 
anti-EGFR mAbs. Therefore, other factors, such as PIK3CA/PTEN 
deregulation and/or the expression status of epiregulin or   
amphiregulin, should also be focused on as possible predictive   
biomarkers for anti-EGFR mAb. 
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